OGI Investment will Fund Proteomic and Transcriptomic Analyses to Further Understand Stem Cells
News Nov 15, 2012
The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regeneration Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions.
MSCs are cells that can differentiate into musculoco-skeletal tissues such as bone, cartilage and muscle. Their ability to generate replacement tissues and affect cellular processes such as inflammation makes them an exciting potential therapy for a variety of conditions. Unlike other cells, MSCs can be used without the need for tissue matching and can be accumulated in large numbers. TRT has developed new methods to extract MSCs from umbilical cords, eliminating many of the challenges related to MSC harvesting from other tissue sources.
“Stem cell research is a promising area of biomedical research and it could have significant impact for people suffering from many conditions,” said Mark Poznansky, President and CEO, OGI. “TRT is an excellent example of an Ontario company developing innovative therapies and translating research into potential clinical applications.”
TRT is aiming to launch clinical trials to test these cells within the next two years. The PBDF funding from OGI will fund proteomic and transcriptomic analyses to further understand TRT’s stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.
“We believe that these stem cells represent a unique and potent means of treating multiple debilitating diseases,” said John Davies, CEO of TRT. “The OGI funding will enable us to demonstrate the utility of our cells for clinical applications using cutting edge technologies.”
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
Using Milk Protein to 3D-Imprint Muscle and Bone CellsNews
Researchers from the University of Canterbury are replicating a 3D imprint of cells onto films made of milk protein. The films then gradually degrade, leaving the grown tissue behind.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018